Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1425-1434

  Valero, Vicente ^a   Buzdar, Aman U ^a   Theriault, Richard L ^a   Azarnia, Nozar ^a   Fonseca, Gustavo A ^a   Willey, Jie ^a   Ewer, Michael ^a   Walters, Ronald S ^a   Mackay, Bruce ^a   Podoloff, Donald ^a   Booser, Daniel ^a   Lee, Lily W ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EVACET; FLUOROURACIL; LIPOSOME; RAZOXANE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE;

EID: 0032895785     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1425     Document Type: Article

References (27)

1. Honing SF: Treatment of metastatic disease, hormonal therapy and chemotherapy, in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1996, pp 669-734
2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
4. Shan K, Lincoff AM, Young JB : Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996
5. Stewart CF, Ratain MJ: Pharmacology of cancer chemotherapy, in DeVita VT, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1997, pp 453-466
6. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
7. Ewer MS, Benjamin RS: Cardiac complications, in Holland JF, Frei III E, Bast RC Jr, et al (eds): Cancer Medicine (ed 3). Baltimore, MD, Williams and Wilkins, 1997, pp 3197-3215
8. Basser RL, Green MD: Complications of treatments: Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 19:57-77, 1993
9. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
10. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
11. Chlebowski RT, Paroly WS, Pugh RP, et al: Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47-51, 1980
12. Torti FM, Bristow MF, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule, assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983
13. Basser RL, Sobol MM, Duggan G, et al: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 12:1659-1666, 1994
14. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
15. Perez-Soler R: Liposomes as carriers of antitumor agents: Toward a clinical reality. Cancer Treat Rev 16:67-82, 1989
16. Gabizon AA: Liposomal anthracyclines. Hematol Oncol Clin North Am 2:431-439, 1994
17. Creaven PJ, Cowens JW, Ginsberg R, et al: Clinical studies with liposomal doxorubicin. J Liposome Res 1:481-490, 1990
18. Cowens JW, Creaven PJ, Greco WR, et al: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 53:2796-2802, 1993
19. Batist G, Ahlgren P, Panasci L, et al: Phase II study of liposomal doxorubicin (TLCD99) in metastatic breast cancer. Proc Am Soc Clin Oncol 11:82, 1992 (abstr 155)
20. Mackay B, Keyes LM, Benjamin RB, et al: Cardiac biopsy. Texas Society Electron Microscopy J 11:7,9-11, 14-15, 1980
21. Jones SE, Durie BGM, Salmon SE: Combination chemotherapy with Adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36:90-97, 1975
22. Hortobagyi GN, Gutterman JU, Blumenschein GR, et al: Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG. Cancer 43:1225-1233, 1979
23. Ewer MS, Ali MK, Mackay B, et al: A comparison of cardiac biopsy grades and ejection fraction estimation in patients receiving Adriamycin. J Clin Oncol 2:112-117, 1984
24. Kanter PM, Bullard GA, Pilkiewicz FG, et al: Preclinical toxicology study of liposome-encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7:85-95, 1993
25. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
26. Hudis C, Seidman A, Paton V, et al: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res Treat, 50:232, 1998 (abstr 24)
27. Batist G, Winer E, Harris L, et al: Phase III study of liposome-encapsulated doxorubicin (TLC D-99) vs. free doxorubicin in patients with metastatic breast cancer. Breast Cancer Res Treat, 50:233, 1998 (abstr 26)